

Title (en)
USE OF EFLUCIMIBE FOR THE PRODUCTION OF A MEDICAMENT FOR THE PREVENTION OR TREATMENT OF A DISEASE CAUSED BY SEBACEOUS GLAND DYSFUNCTION IN HUMANS OR ANIMALS

Title (de)
VERWENDUNG VON EFLUCIMIBE ZUR HERSTELLUNG EINES MEDIKAMENTS ZUR VORBEUGUNG ODER BEHANDLUNG EINER DURCH TALGDRÜSENDYSFUNKTION HERBEIGEFÜHRTEN KRANKHEIT BEI TIEREN ODER MENSCHEN

Title (fr)
UTILISATION DE L'ÉFLUCIMIBE POUR LA PRÉPARATION D'UN MÉDICAMENT DESTINÉ À PRÉVENIR OU À TRAITER UNE MALADIE DUE À DYSFONCTIONNEMENT DES GLANDES SÉBACÉES CHEZ L'HOMME OU L'ANIMAL

Publication
EP 2167067 A1 20100331 (FR)

Application
EP 08826957 A 20080717

Priority
• FR 2008051341 W 20080717
• FR 0756604 A 20070719

Abstract (en)
[origin: WO2009019385A1] The invention relates to the use of at least one of the compounds (S)-2-dodecylsulfanyl-N-(4-hydroxy-2,3,5-trimethyl-phenyl)-2-phenyl-acetanilide (eflucimibe) of formula (I), (R)-2-dodecylsulfanyl-N-(4-hydroxy-2,3,5-trimethyl-phenyl)-2-phenyl-acetanilide ((R) enantiomer), and the pharmaceutically acceptable salts and solvates thereof for producing a medicament or a dermatological composition for preventing and treating disorders caused by sebaceous gland dysfunction and/or any state or disease related to excess sebum production in humans or animals.

IPC 8 full level
A61K 31/167 (2006.01); **A61K 9/06** (2006.01); **A61K 9/12** (2006.01); **A61K 9/14** (2006.01); **A61K 9/70** (2006.01); **A61P 17/08** (2006.01); **A61P 17/10** (2006.01)

CPC (source: EP US)
A61K 31/167 (2013.01 - EP US); **A61P 17/00** (2018.01 - EP); **A61P 17/08** (2018.01 - EP); **A61P 17/10** (2018.01 - EP)

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

Designated extension state (EPC)
AL BA MK RS

DOCDB simple family (publication)
FR 2918889 A1 20090123; **FR 2918889 B1 20091023**; CA 2692837 A1 20090212; EP 2167067 A1 20100331; US 2010172957 A1 20100708; WO 2009019385 A1 20090212

DOCDB simple family (application)
FR 0756604 A 20070719; CA 2692837 A 20080717; EP 08826957 A 20080717; FR 2008051341 W 20080717; US 68827710 A 20100115